← Back to Search

Biological

Autologous platelet rich plasma eye drops for Dry Eye Syndrome

Phase 4
Waitlist Available
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 6 and 12 weeks visit
Awards & highlights

Study Summary

This trial will study whether autologous platelet rich plasma, or aPRP, can help improve symptoms and clinical signs in cases of moderate to severe ocular surface disease.

Eligible Conditions
  • Dry Eye Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 6 and 12 weeks visit
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 6 and 12 weeks visit for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mean change from baseline in Ocular Surface Disease Index (OSDI) score questionnaire
Secondary outcome measures
Mean change from baseline of Corneo-conjunctival staining score

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment groupExperimental Treatment1 Intervention
Participant with moderate to sever ocular surface disease will be treated with autologous platelet rich plasma eye drops

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor
1,473 Previous Clinical Trials
484,905 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this clinical research accept participants below the age of sixty?

"This clinical trial has established age inclusion criteria of 18 to 99, however there are two separate studies for those under the legal age and 77 additional trials for people above 65."

Answered by AI

Are there vacancies available in this medical experiment?

"The clinicialtrials.gov portal states that this trial has ceased to accept new recruits, with the first posting being dated January 1st 2021 and its most recent edit occurring on October 22nd 2020. Despite this study having closed recruitment, 79 other trials are still taking in participants at present."

Answered by AI

Is Autologous platelet rich plasma eye drops a secure treatment for patients?

"As this treatment is approved, Autologous platelet rich plasma eye drops was rated a 3 on our safety scale."

Answered by AI

What types of individuals are ideal candidates for this trial?

"This research seeks to enrol 100 people aged between 18 and 99 with dry eye. To be eligible, applicants must have moderate or severe ocular surface disease based on the NEI/Industry Grading System's fluorescein corne-conjunctival staining score of 5 or higher as well as an OSDI questionnaire score of 20 or more after at least one month of treatment with non-preserved artificial tears 4 times a day."

Answered by AI

Who else is applying?

How old are they?
65+
What site did they apply to?
Toronto Western Hospital
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Platelet Rich Plasma Eye Drops for Treatment of Ocular Surface Disease
Allan Slomovic 2021. "Platelet Rich Plasma Eye Drops for Treatment of Ocular Surface Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04608084.
~24 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top